Merck stock has delivered a strong 92.2% return over the past 5 years, yet its current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting the shares may sit below what the underlying cash flows imply while market multiples look closer to fair.

• A 92.2% gain over 5 years puts Merck among the stronger large pharma performers, which raises the question of how much of its pipeline and cash flow potential is already reflected in the price.
• Recent FDA approval for the oral PCSK9 pill Lipfendra can support expectations for future cash flows, while concentration risk around the Keytruda patent cliff remains a key factor for how durable those cash flows may be.
• Merck scores 3 out of 6 on the valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Merck's current price already captures this blend of new products, pipeline optionality, and patent risks, or if the intrinsic value implied by the DCF still leaves a margin of safety.

Is Merck Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model uses Merck’s projected free cash flows to estimate what the stock could be worth today. Merck currently generates about $14.0b in latest twelve month free cash flow, and the DCF framework applies a growing cash flow profile over time to those starting levels. On that basis, the model arrives at an estimated intrinsic value of about $216 per share.

With that intrinsic value sitting above the current share price, the DCF output indicates that Merck stock screens at around 41.0% undervalued based on these cash flow assumptions. The recent FDA approval of the oral PCSK9 pill Lipfendra adds another potential long term cash flow source, which helps explain why the cash flow based model can still sit above the market price even as investors weigh the Keytruda patent cliff.

Overall, the Discounted Cash Flow analysis suggests Merck stock currently appears undervalued relative to the cash it is projected to generate.

Our Discounted Cash Flow (DCF) analysis suggests Merck is undervalued by 41.0%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Does Merck Look Fairly Valued on Earnings?

The P/E multiple is a useful way to look at Merck because earnings are still a central anchor for how investors value large pharmaceutical stocks. Merck currently trades on a P/E of about 35.2x, which sits above the broader pharmaceuticals industry average of 15.0x and also above the peer average of 26.7x.

The tailored fair P/E ratio for Merck is 36.0x, which reflects what investors might typically pay given its earnings profile, size and risk mix. With the actual P/E only slightly below this fair ratio, the stock does not screen as meaningfully cheap or expensive on earnings, even though it carries a premium to the industry average and peers.

On the P/E multiple, Merck stock appears roughly fairly valued, with its current earnings premium largely in line with what the model suggests is reasonable.

The Merck Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Merck's mixed valuation picture leaves off by spelling out which assumptions about Merck's future growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today's price. Each Narrative ties a specific fair value estimate to a particular view of Merck's potential catalysts and key risks, so you can see over time which version of the story appears closer to reality on the Community page.

Merck investors are split between a pipeline heavy bull story and a pricing and patent risk focused bear case.

Bull case: roughly fairly valued

"With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth…"

Bear case: 25% overvalued

"Intensifying global pressure on drug pricing from policymakers, insurers, and patients, including the prospect of government-mandated price cuts and the impending impact of the Inflation Reduction Act, threatens to erode future revenue growth and compress net margins across Merck's flagship and pipeline products…"

Do you think there's more to the story for Merck? Head over to our Community to see what others are saying!

The Bottom Line

Merck sits in an interesting middle ground, with the Discounted Cash Flow (DCF) intrinsic value estimate implying meaningful upside while the P/E based view points to a stock that is roughly in line with what the market usually pays for its earnings profile. The mixed valuation checks underline that the cash flow model and market multiples are keying off different things, from long term funding needs and cash flow timing to near term expectations and sentiment.

What matters most from here is whether Merck can convert its late stage pipeline into durable cash flows that offset Keytruda concentration risk, which will help determine if the current discount reflects a potential opportunity or simply compensation for those uncertainties.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.